Genedata, a leading provider of advanced software solutions for R&D, today announced that Sanofi, a global healthcare leader, has chosen Genedata Selector for the management of omics data related to the improvement of their microbial production organisms. Genedata Selector enables Sanofi to significantly save time and resources in selecting the best strains for production by efficiently managing all NGS information related to the optimization of production strains.
One Single Solution to Optimize Processes, Drive Efficiencies, and Reduce Costs
Genedata Selector is an enterprise-level, genome management platform that enables the optimization of mammalian cell lines as well as microbial strains for biopharmaceutical and industrial biotech companies. The platform’s standardized and reproducible workflows automate the processing and analysis of complex data sets such as NGS and gene expression data for cell line optimization. Genedata Selector’s integrated enterprise software platform facilitates collaboration among research groups and sites allowing easy access to all data under one umbrella. Researchers can therefore lower costs and reduce time to market by avoiding unnecessary duplication of work and by promoting efficient decision-making across the organization.
“We are excited that Sanofi has chosen Genedata Selector for its innovative strain optimization projects,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata is committed to collaborating with global leaders of the biopharmaceutical industry to support their highly challenging work of improving production strains. Our 20 years of experience combined with our innovative Genedata Selector platform positions us in a unique way to offer cutting edge technology and world-class support.
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.